China Biopharmaceuticals (01177) rose more than 4%. As of press release, it rose 4.06% to HK$3.33, with a turnover of HK$281 million.
The Zhitong Finance App learned that China Biopharmaceuticals (01177) rose by more than 4%. As of press release, it had risen 4.06% to HK$3.33, with a turnover of HK$281 million.
According to the news, China Biopharmaceutical recently announced that the two innovative drugs “anlotinib hydrochloride capsules” and “TQB2916 (CD40 agonist)” developed by Chia Tai Tianqing will announce 5 research results at the 2024 American Cancer Association Annual Meeting AACR. According to reports, anlotinib is a novel oral small-molecule multi-target receptor tyrosine kinase inhibitor (TKI), which can effectively inhibit VEGFR 1-3 kinases. By regulating tumor microenvironment reprogramming, it can inhibit tumor angiogenesis, inhibit tumor growth, and regulate the immune microenvironment. CD40 agonists mainly exert tumor suppression effects by activating antigen-presenting cells (APC) to promote the activation of immune cells.